# Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

> **NCT00063999** · PHASE3 · COMPLETED · sponsor: **GOG Foundation** · enrollment: 1381 (actual)

## Conditions studied

- Recurrent Uterine Corpus Carcinoma
- Stage IIIA Uterine Corpus Cancer AJCC v7
- Stage IIIB Uterine Corpus Cancer AJCC v7
- Stage IIIC Uterine Corpus Cancer AJCC v7
- Stage IVA Uterine Corpus Cancer AJCC v7
- Stage IVB Uterine Corpus Cancer AJCC v7

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Doxorubicin Hydrochloride
- **BIOLOGICAL:** Filgrastim
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** Pegfilgrastim
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT00063999
- **Lead sponsor:** GOG Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08-25
- **Primary completion:** 2013-06-29
- **Final completion:** 2021-01-05
- **Target enrollment:** 1381 (ACTUAL)
- **Last updated:** 2021-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00063999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00063999, "Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00063999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*